title: Antihypertensive effect of oral potassium aspartate supplementation in mild to moderate arterial hypertension.
abstract: BACKGROUND
  Previous studies showed that potassium chloride (48-120 mmol/day) supplementation reduced arterial blood pressure (BP) in hypertensive patients.
  
  
  OBJECTIVE
  Our aim was to evaluate the effect of a lower dose of potassium aspartate salt on BP in individuals with essential arterial hypertension.
  
  
  METHODS
  One hundred and four patients (65 males, age 53 +/- 12 years) with mild to moderate essential hypertension (systolic/diastolic BP 154.2/96.2 +/- 10.8/5.4 mmHg) were allocated in two comparable groups of 52 to receive or not 30 mmol/day per os of potassium aspartate supplementation for four weeks. Office and 24-h BP, as well as serum and urinary electrolytes, were measured at baseline and at the follow-up visit after four weeks.
  
  
  RESULTS
  Office and 24-h BP did not change in the control group, while these values were significantly reduced in the potassium supplementation group. Changes in office (systolic BP: 154.4 +/- 8.2 vs. 142.2 +/- 7.6 mmHg; diastolic BP: 95.0 +/- 5.6 vs. 87.2 +/- 4.3 mmHg, P < 0.001 for both) and 24-h BP (systolic BP: 142.7 +/- 8.2 vs. 134.8 +/- 6.3 mmHg; diastolic BP: 90.8 +/- 4.4 vs. 84.6 +/- 3.8 mmHg, P < 0.001 for both) following potassium supplementation were highly significant. The changes in day time and night time BP were similar. The treated group showed significantly increased potassium serum level and 24-h urinary excretion of potassium (P < 0.01 in both cases) after four weeks, while the untreated group showed no significant changes of the same parameters. Urinary Na/K ratio decreased significantly with potassium supplementation (P < 0.001). In the treated group changes in office (r = 0.58, P < 0.001) and 24-h SBP (r = 0.51, P < 0.001), but not in DBP (r = 0.29 and r = 0.25, n.s.), correlated positively with the urinary Na/K ratio at baseline.
  
  
  CONCLUSIONS
  A relatively low supplementation of 30 mmol/day of potassium as aspartate lowered office and 24-h ambulatory BP in subjects with mild to moderate essential hypertension. The antihypertensive effect was sustained throughout the day, and was greater in the patients with high basal urinary Na/K ratio.
authors.affiliation: Department of Internal Medicine, University of Pisa School of Medicine, via Roma 67, 56126 Pisa, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Franzoni
authors.forename: G
authors.initials: G
authors.lastname: Santoro
authors.forename: A
authors.initials: A
authors.lastname: Carpi
authors.forename: F
authors.initials: F
authors.lastname: Da Prato
authors.forename: F
authors.initials: F
authors.lastname: Bartolomucci
authors.forename: F R
authors.initials: FR
authors.lastname: Femia
authors.forename: F
authors.initials: F
authors.lastname: Prattichizzo
authors.forename: F
authors.initials: F
authors.lastname: Galetta
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001224:Aspartic Acid / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D016014:Linear Models; D008297:Male; D008875:Middle Aged
chemical_list: D000959:Antihypertensive Agents; D001224:Aspartic Acid